The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference32 articles.
1. Randomised proof-of-concept Phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial;Le Tourneau;Br. J. Cancer,2014
2. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;Wolff;J. Clin. Oncol.,2013
3. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial;Smith;Lancet,2007
4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N. Engl. J. Med.,2001
5. The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information;Welch;J. Pers. Med.,2013
Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Semantic Integration of BPMN Models and FHIR Data to Enable Personalized Decision Support for Malignant Melanoma;Information;2023-12-06
2. Molecular tumour boards — current and future considerations for precision oncology;Nature Reviews Clinical Oncology;2023-10-16
3. Actionability classification of variants of unknown significance correlates with functional effect;npj Precision Oncology;2023-07-15
4. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation;Cancer Chemotherapy and Pharmacology;2023-06-14
5. Understanding inequities in precision oncology diagnostics;Nature Cancer;2023-05-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3